This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

63/100

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Disease modifying drugs for Alzheimer's disease (AD) are likely to be most effective when given in non-demented subjects. In this review we summarized biomarkers in cerebrospinal fluid (CSF) and blood that can predict AD-type dementia in subjects with mild cognitive impairment (MCI). In addition, we investigated whether these markers could reduce sample size and costs if used to select subjects for trials on the prevention of AD in subjects with MCI.

Key findings

In this review we summarized biomarkers in cerebrospinal fluid (CSF) and blood that can predict AD-type dementia in subjects with mild cognitive impairment (MCI).
In addition, we investigated whether these markers could reduce sample size and costs if used to select subjects for trials on the prevention of AD in subjects with MCI.
A meta-analysis of markers that had been investigated in multiple studies showed that the combination of amyloid-beta (Abeta1-42 and tau in CSF had the best predictive accuracy for AD (odds ratio (OR) 18.1, 95% confidence interval (CI) 9.6-32.4).
Abeta1-42, total tau, and phosphorylated tau in CSF also predicted conversion, but with lower accuracy (OR 7.5 to 8.1).

Why it matters

This review and meta-analysis summarized CSF and blood biomarkers that predict conversion from mild cognitive impairment to Alzheimer-type dementia and examined whether they could reduce sample size and costs in prevention trials. It is a methodological review and does not itself test any treatment, cure, or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designmeta-analysis
Effect sizeOR 7.5
Evidence strengthHigh

How this study scored 63/100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size and studied in people because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD)
Journal's citation record	2 / 4	Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design	12 / 12	A meta-analysis pooling many studies
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2010 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	3 / 3	Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	A review of other studies — randomisation is not credited here
Times cited	5 / 7	Cited 145 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	8.1 citations a year over 18 year(s) since 2010
Impact for its field and year	4 / 6	Cited 10.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 12 other studies in this library
Still being cited	1 / 4	Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Pieter Jelle Visser: h-index 90 (OpenAlex, whole career)
Institution's track record	1 / 3	Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 20413876)
Free to read	0 / 2	Behind a paywall — scores zero
Total	63 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

van Rossum, I. A., Vos, S., Handels, R., & Visser, P. J. (2010). Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-2010-091606

Vancouver

van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer's disease : JAD. 2010. doi:10.3233/jad-2010-091606. PMID: 20413876.

BibTeX

@article{vanrossum2010-20413876,
  author  = {van Rossum, I. A. and Vos, S. and Handels, R. and Visser, P. J.},
  title   = {{Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2010},
  doi     = {10.3233/jad-2010-091606},
  pmid    = {20413876},
  url     = {https://doi.org/10.3233/jad-2010-091606}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Later studies that cite this one

12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →